# DT120

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/dt120
Canonical HTML page: https://getbiobrief.com/entity/dt120

## Timeline

- **2026-02-19**: Jefferies Analyst Note — Jefferies issues high-conviction 65-75% probability for best-in-class efficacy.
- **2026**: Anticipated Readout — Expected top-line data from the Phase III DT120 trial.
- **2025-Q4**: Phase III Initiation — Global Phase III trial for DT120 begins enrollment.
- **2025-Q3**: Phase II Success — Definium publishes robust Phase II data for DT120.

## Recent coverage (1 stories)

### Jefferies Bullish on Definium's DT120: 75% Odds for Best-in-Class Efficacy
2026-02-19 05:47:55 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Jefferies analysts have issued a high-conviction outlook on Definium Therapeutics' lead candidate, DT120, assigning a 65-75% probability that the drug will demonstrate best-in-class efficacy in its ongoing Phase III trials. This projection positions the company as a potential disruptor in its therapeutic category, significantly raising market expectations ahead of upcoming data readouts.
Full story: https://getbiobrief.com/story/definium-therapeutics-dt120-phase-3-jefferies-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.